Warning
Fagron Compounding Services Recalls Vancomycin HCI
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0440-2026Drug / Pharmaceutical
Fagron Compounding Services Recalls Vancomycin HCI
Fagron Compounding Services · Class II — Moderate Risk
Product Description
Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5083-01
Reason for Recall
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Nationwide in the U.S.A.
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
A Class II FDA recall has been issued for a pharmaceutical product from Fagron Compounding Services, initiated on March 20, 2026. Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port. This recall covers 34,260 bags, distributed nationwide. While not the highest severity, consumers should exercise caution and stop using the product until the recall is resolved.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medication Defects.